TG Therapeutics, Inc. or Iovance Biotherapeutics, Inc.: Who Invests More in Innovation?

Biotech Giants' R&D Spending: A Decade of Innovation

__timestampIovance Biotherapeutics, Inc.TG Therapeutics, Inc.
Wednesday, January 1, 2014270459731354781
Thursday, January 1, 20151547000043445817
Friday, January 1, 20162803700066489820
Sunday, January 1, 20177161500096886134
Monday, January 1, 201899828000153793000
Tuesday, January 1, 2019166023000148369000
Wednesday, January 1, 2020201727000151934000
Friday, January 1, 2021259039000198532000
Saturday, January 1, 2022294781000112128000
Sunday, January 1, 202334407700076192000
Loading chart...

Igniting the spark of knowledge

Innovation Race: TG Therapeutics vs. Iovance Biotherapeutics

In the dynamic world of biotechnology, innovation is the lifeblood of progress. Over the past decade, TG Therapeutics and Iovance Biotherapeutics have been at the forefront, investing heavily in research and development (R&D) to pioneer groundbreaking therapies. From 2014 to 2023, Iovance Biotherapeutics has consistently outpaced TG Therapeutics in R&D spending, with a staggering 132% increase in their investment, peaking at $344 million in 2023. In contrast, TG Therapeutics saw a more modest 143% growth, reaching $76 million in the same year. This trend highlights Iovance's commitment to innovation, as they allocate a larger portion of their resources to R&D. As these companies continue to push the boundaries of medical science, their financial strategies offer a glimpse into the future of biotech innovation. Stay tuned as we delve deeper into how these investments translate into clinical breakthroughs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025